<DOC>
	<DOCNO>NCT00242814</DOCNO>
	<brief_summary>The objective study compare PPAR activity ( increase adiponectin level ) MICARDIS amlodipine 6 week treatment hypertensive patient metabolic syndrome . Moreover , study compare serum level inflammatory marker metabolic syndrome 6 week treatment . An ancillary study perform one center ass adipocyte differentiation ( PPAR gamma stimulation ) 30 subject ( 15 per arm ) .</brief_summary>
	<brief_title>Phase IV , 9 Weeks Comparison Between MICARDIS 80 mg Amlodipine 10 mg Biological PPAR Gamma Activities</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patient write informed consent sign prior trial specific procedure participation male patient &gt; 18 year Mean seat SBP &gt; 130mmHg and/or DBP &gt; 85mmHg treated antihypertensive drug ( ) least 2 criterion metabolic syndrome ( NCEPT III ) . Biological data available within 6 month prior enrollment visit . abdominal obesity &gt; 102 cm screen TG &gt; 1.5 g/l HDL &lt; 0.4 g/l Glycemia &gt; 6 mmol/l Patients follow condition exclude trial : confirm type 1 2 diabetic patient treat secondary hypertension Mean seat SBP &gt; 180 mmHg and/or DBP &gt; 110 mmHg screen hepatic and/or renal dysfunction define follow laboratory parameter visit 1 : SGPT ( ALT ) SGOT ( AST ) ¿ twice upper limit normal range serum creatinine ¿ 2.3 mg/dL ( 203 ¿mol/L ) bilateral renal artery stenosis renal artery stenosis solitary kidney patient postrenal transplant one function kidney clinically relevant hypokalemia hyperkalemia visit 1 uncorrected volume sodium depletion visit 1 primary aldosteronism hereditary know fructose intolerance biliary obstructive disorder patient previously experience symptom characteristic angioedema treatment angiotensinII receptor antagonists history drug alcohol dependency within previous six month concurrent participation another clinical trial investigational therapy within thirty day prior sign consent form symptomatic congestive heart failure ( New York Heart Academy ( NYHA ) functional class CHF IIIV ) unstable angina pectoris , myocardial infarction , percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) surgery less three month prior inform consent stroke less six month prior inform consent sustain ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant arrhythmia determine investigator hypertrophic obstructive cardiomyopathy , hemodynamically relevant stenosis aortic mitral valve know allergic hypersensitivity component formulation investigation concomitant therapy lithium , cholestyramine colestipol resin continue visit 1</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>